Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 50.62 +0.26 (+0.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 28 29 Next > European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment July 17, 2024 European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. Via Benzinga Exposures COVID-19 Stable Blue-Chip Stocks to Buy Before Earnings Season July 17, 2024 Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth. Via InvestorPlace Senate To Review Novo Nordisk's Levemir Insulin Discontinuation July 16, 2024 Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... Via Benzinga Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing July 12, 2024 Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-stakes pharmaceutical industry deals. Via Benzinga Bernie Sanders Targets High Prices of Ozempic and Wegovy In US July 11, 2024 Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. Via Benzinga EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers July 11, 2024 VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a Via Benzinga 3 Stocks to Sell Immediately Based on the French Election Results July 09, 2024 Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts. Via InvestorPlace What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. Via Investor's Business Daily Upcoming Stock Spinoffs: Should You Pounce or Pass? July 04, 2024 Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. Via InvestorPlace 7 Safe Haven Stocks to Buy Before the Next Market Correction July 03, 2024 Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. Via InvestorPlace Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data July 03, 2024 EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... Via Benzinga Exposures Product Safety Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes July 03, 2024 After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock. Via InvestorPlace Exposures COVID-19 Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims July 02, 2024 A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... Via Benzinga Topics Lawsuit Exposures Financial Legal Surprise! 3 Stocks That Are Outperforming Nvidia in 2024. July 01, 2024 There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant July 01, 2024 Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly... Via Benzinga Where Will Novavax Be in 1 Year? June 29, 2024 We will know a lot more about the vaccine maker's long-term prospects in 12 months. Via The Motley Fool First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product June 27, 2024 The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. Via Benzinga Exposures Product Safety Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? June 27, 2024 Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. Via InvestorPlace Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC June 26, 2024 Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. Via Benzinga Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer June 20, 2024 GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. Via Benzinga Topics Lawsuit Exposures Financial Legal Is It Too Late to Buy Novavax Stock? June 14, 2024 Shares of the vaccine maker are trading up 230% this year. Via The Motley Fool Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks June 13, 2024 The companies are closing in on the finish line for two new COPD treatments. Via Investor's Business Daily Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club June 12, 2024 Enthusiasm is growing for a looming approval in COPD treatment. Via Investor's Business Daily A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge June 12, 2024 The integration of AI and healthcare is well underway. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Bull Market and Beyond: 3 Stocks Just Waiting to Soar June 11, 2024 These pharma and biotech players could become long-term winners. Via The Motley Fool Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK June 10, 2024 If approved, this would be the first combination vaccine based on mRNA technology to hit the market. Via Investor's Business Daily Exposures COVID-19 Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar June 07, 2024 These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. Via InvestorPlace The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash June 07, 2024 Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. Via InvestorPlace Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients June 04, 2024 Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 28 29 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.